Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862423 | 1.00 | ALDH1A1 (0.32) | ALDH1A1LMNAKDM4EPDE4APDE4B | |
| SCHEMBL8768253 | 0.94 | DRD2 (0.32) | ALDH1A1LMNAKDM4ECYP1A2CYP3A4 | |
| SCHEMBL30912777 | 0.94 | DRD2 (0.32) | ALDH1A1LMNAKDM4ECYP1A2CYP3A4 | |
| SCHEMBL8223255 | 0.94 | ALDH1A1 (0.36) | ALDH1A1LMNAKDM4EPDE4APDE4B | |
| SCHEMBL19279280 | 0.90 | DRD2 (0.33) | ALDH1A1LMNAKDM4EPDE4APDE4B | |
| SCHEMBL22336204 | 0.88 | LMNA (0.35) | ALDH1A1LMNAKDM4EPDE4APDE4B | |
| SCHEMBL22286624 | 0.88 | KDM4E (0.32) | ALDH1A1LMNAKDM4EPDE4APDE4B | |
| SCHEMBL23456703 | 0.86 | ALDH1A1 (0.33) | ALDH1A1LMNAKDM4EPDE4APDE4B | |
| SCHEMBL29987680 | 0.86 | ALDH1A1 (0.33) | ALDH1A1LMNAKDM4EPDE4APDE4B | |
| SCHEMBL8769102 | 0.85 | ALDH1A1 (0.36) | ALDH1A1LMNAKDM4EPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891368-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2024-02-06 | — | — | US | disclosed |
| EP-4069361-B1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-01-03 | — | — | EP | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| EP-3921027-B1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-07-19 | — | — | EP | disclosed |
| EP-3921027-B1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-07-19 | — | — | EP | disclosed |
| EP-4069361-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2022-10-12 | — | — | EP | disclosed |
| US-20220162176-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2022-05-26 | — | — | US | disclosed |
| US-20220162176-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2022-05-26 | — | — | US | disclosed |
| WO-2021110886-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021110886-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | WO | disclosed |
| US-20210147372-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-05-20 | — | — | US | disclosed |
| US-20210147372-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-05-20 | — | — | US | disclosed |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | Aibireo AB (SE) | 2021-04-13 | — | — | US | disclosed |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | Aibireo AB (SE) | 2021-04-13 | — | — | US | disclosed |
| WO-2020161216-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020161216-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | disclosed |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | ALDH1A1 706/4885LMNA 2925/4885KDM4E 2541/4885 |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | ALDH1A1 706/4885LMNA 2925/4885KDM4E 2541/4885 |
| US-20220162176-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | ALDH1A1 1005/4885LMNA 3377/4885KDM4E 1971/4885 |
| US-20210147372-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | ALDH1A1 706/4885LMNA 2925/4885KDM4E 2541/4885 |
| US-11891368-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | ALDH1A1 1005/4885LMNA 3377/4885KDM4E 1971/4885 |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | ALDH1A1 706/4885LMNA 2925/4885KDM4E 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.